The global functional ingredient market is experiencing a profound paradigm shift.
Consumers and health practitioners are moving away from broad-spectrum, generic probiotic supplementation in favor of strain-specific, clinically validated interventions. As understanding of human microbiome advances, ingredient innovators are focusing intensely on metabolic optimization.
At the upcoming Growth Asia 2026 conference, TCI will highlight how survival mechanics and targeted bioactivity are redefining product formulation. Translating laboratory discovery into stable, commercially viable consumer products requires overcoming the inherent vulnerabilities of live microorganisms. Through rigorous clinical validation and innovative delivery platforms, industry players are successfully unlocking the systemic potential of targeted functional strains.
Metabolic optimization and hepatoprotection
The bidirectional communication axis between the gastrointestinal tract and the liver represents a major regulatory pathway for human metabolic health. Dysbiosis within the gut can compromise intestinal barrier integrity, allowing microbial toxins and environmental metabolic byproducts to translocate into the portal vein, the primary means of absorbing water-soluble nutrients.1
This influx triggers oxidative stress and inflammatory cascades within hepatic tissue, accelerating lipid accumulation and contributing to the progression of non-alcoholic fatty liver disease (NAFLD).2
To target this pathway, TCI researchers isolated a unique spore-forming, lactic acid-producing probiotic strain from organic apple pomace: ActivPro (Weizmannia coagulans). In vitro testing confirmed that the endospores of ActivPro successfully resist destructive exposure to simulated gastric acid (pH 3) and 0.3% bile acid solutions, ensuring high viability upon reaching the intestinal tract.3
Dual-action enzymatic bioactivity: Alcohol elimination
Qualitative proteomic profiling via ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) revealed that ActivPro naturally synthesizes key metabolic detoxification enzymes, specifically alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). These enzymes represent the body’s primary pathway for degrading ethanol into non-toxic acetate.3
This enzymatic capacity was validated in a clinical trial published in the International Journal of Food Sciences and Nutrition. Healthy adults consumed one ActivPro capsule daily for one week before undergoing an acute oral alcohol challenge (75ml of 40% v/v whisky). Breath alcohol concentration (BrAC) tracking revealed that the ActivPro group achieved a significantly faster alcohol clearance rate compared to baseline measurements.
Most notably, the active group effectively metabolized the full alcohol challenge, recording a BrAC of 0mg/L within 120 minutes of consumption.3 This accelerated metabolic clearing directly correlated with a reduction in hangover severity indicators, including headache, dizziness, and loss of concentration.
ActivPro regulated gut microbiota. The subjects (n = 43) received one ActivPro capsule or placebo daily for 8 weeks. Thereafter, a subject’s feces was collected and analyzed by next-generation sequencing for the relative abundance (%) of (A) Bifidobacterium, (B) Eubacterium, (C) Ruminococcaceae, and (D) Sellimonas, compared with baseline (week 0) (P < 0.05, **P < 0.01). #, compared with the placebo group (P < 0.05).
Clinical efficacy in hepatic steatosis
Building upon these metabolic findings, a second clinical trial published in Current Developments in Nutrition evaluated the strain’s long-term impact on chronic hepatic fat deposition.
In a randomized, double-blind, placebo-controlled trial, 57 patients diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD) received either a placebo or a daily capsule containing 100mg of ActivPro for eight weeks.4 Hepatic fat content was quantified noninvasively using FibroScan to capture controlled attenuation parameter (CAP), a validated indicator of liver fat content and health.
The trial demonstrated improvements in liver tissue composition:4
- Targeted fatty liver reduction: The entire active cohort experienced an average 5.2% reduction in CAP values. When adjusting the data to exclude severely obese individuals (BMI >30kg/m2) to reduce ultrasound elastography variance, the ActivPro group achieved a highly significant 8.7% net reduction in liver fat content compared to the placebo group.
- Down-grading of fatty liver severity: Standard histological grading showed that seven participants in the ActivPro group achieved a lower fatty liver classification. Six individuals successfully decreased from severe steatosis (S3) to a moderate (S2) level, while another shifted from mild steatosis (S1) to a completely normal, fat-free status (S0).
- Microbiota reshaping: Fecal next-generation sequencing (NGS) tracking verified that these changes were driven by a complete reorganization of the gut ecosystem. Supplementation significantly expanded the relative abundance of hepatoprotective and short-chain fatty acid (SCFA) producing genera, notably Bifidobacterium, Eubacterium, Ruminococcaceae, and Sellimonas.5,6,7
Overcoming delivery challenges with leading liquid chocolate encapsulation
The identification of a high-performance probiotic strain represents only the initial phase of commercial ingredient development. The ultimate efficacy of any biotic product depends entirely on viable delivery, ensuring that an adequate population of colony-forming units (CFU) survives manufacturing, shelf storage, and passage through gastric acid and bile salts to colonize the intestinal tract. Live cells frequently suffer high mortality rates when exposed to ambient moisture, oxygen, and low-pH gastric environments.
TCI’s chocolate platform utilizes a protective liquid delivery matrix. This specialized formulation suspends the functional microorganism within a structural matrix composed of lipid and cocoa. The hydrophobic properties of lipid suspension create a physical barrier that prevents ambient moisture from prematurely activating the dormant microorganisms during storage, resulting in a stable shelf life for over 18 months.
Upon ingestion, the lipid envelope insulates the probiotics from destructive interactions with gastric juices and bile salts. This protection ensures that the bacteria pass through the stomach intact, allowing them to successfully colonize and exert their metabolic effects within the gut.
By embedding functional ingredients into an indulgent format, this delivery system addresses a major commercial challenge: consumer compliance. Traditional pill and capsule formats often lead to pill fatigue and less compliance, whereas format innovations allow manufacturers to deliver clinically supported dosages in a practical, appealing consumer experience.
References
- Chen, Z.; et al. The Gut‒Liver Axis in Liver Disease: Molecular Mechanisms and Therapeutic Targets. MedComm6. 2025; 11: e70458.
- Song, Q.; et al. The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC. Biomedicines. 2022 Feb 23;10(3):524.
- Huang, C.; et al. The applications of B. coagulans TCI711 in alcohol elimination. International Journal of Food Sciences and Nutrition. 2020; 72(5), 713–719.
- Hsieh, R.; et al. Bacillus coagulans TCI711 Supplementation Improved Nonalcoholic Fatty Liver by Modulating Gut Microbiota: A Randomized, Placebo-Controlled, Clinical Trial. Current Developments in Nutrition. 2024; 8:3.
- Wang, L.; et al. Bifidobacterium bifidum Shows More Diversified Ways of Relieving Non-Alcoholic Fatty Liver Compared with Bifidobacterium adolescentis. Biomedicines. 2022; 10, 84.
- Engels, C.; et al. The Common Gut Microbe Eubacterium hallii also Contributes to Intestinal Propionate Formation. Front. Microbiol. 2016; 7.
- Milton-Laskibar, I.; et al. Effects of Resveratrol Administration in Liver Injury Prevention as Induced by an Obesogenic Diet: Role of Ruminococcaceae. Biomedicines. 202210(8), 1797.
